Novel Benchmark Values for Redo Liver Transplantation: Does the Outcome Justify the Effort?


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
01 11 2022
Historique:
pubmed: 28 7 2022
medline: 12 10 2022
entrez: 27 7 2022
Statut: ppublish

Résumé

To define benchmark cutoffs for redo liver transplantation (redo-LT). In the era of organ shortage, redo-LT is frequently discussed in terms of expected poor outcome and wasteful resources. However, there is a lack of benchmark data to reliably evaluate outcomes after redo-LT. We collected data on redo-LT between January 2010 and December 2018 from 22 high-volume transplant centers. Benchmark cases were defined as recipients with model of end stage liver disease (MELD) score ≤25, absence of portal vein thrombosis, no mechanical ventilation at the time of surgery, receiving a graft from a donor after brain death. Also, high-urgent priority and early redo-LT including those for primary nonfunction (PNF) or hepatic artery thrombosis were excluded. Benchmark cutoffs were derived from the 75th percentile of the medians of all benchmark centers. Of 1110 redo-LT, 373 (34%) cases qualified as benchmark cases. Among these cases, the rate of postoperative complications until discharge was 76%, and increased up to 87% at 1-year, respectively. One-year overall survival rate was excellent with 90%. Benchmark cutoffs included Comprehensive Complication Index CCI ® at 1-year of ≤72, and in-hospital and 1-year mortality rates of ≤13% and ≤15%, respectively. In contrast, patients who received a redo-LT for PNF showed worse outcomes with some values dramatically outside the redo-LT benchmarks. This study shows that redo-LT achieves good outcome when looking at benchmark scenarios. However, this figure changes in high-risk redo-LT, as for example in PNF. This analysis objectifies for the first-time results and efforts for redo-LT and can serve as a basis for discussion about the use of scarce resources.

Sections du résumé

OBJECTIVE
To define benchmark cutoffs for redo liver transplantation (redo-LT).
BACKGROUND
In the era of organ shortage, redo-LT is frequently discussed in terms of expected poor outcome and wasteful resources. However, there is a lack of benchmark data to reliably evaluate outcomes after redo-LT.
METHODS
We collected data on redo-LT between January 2010 and December 2018 from 22 high-volume transplant centers. Benchmark cases were defined as recipients with model of end stage liver disease (MELD) score ≤25, absence of portal vein thrombosis, no mechanical ventilation at the time of surgery, receiving a graft from a donor after brain death. Also, high-urgent priority and early redo-LT including those for primary nonfunction (PNF) or hepatic artery thrombosis were excluded. Benchmark cutoffs were derived from the 75th percentile of the medians of all benchmark centers.
RESULTS
Of 1110 redo-LT, 373 (34%) cases qualified as benchmark cases. Among these cases, the rate of postoperative complications until discharge was 76%, and increased up to 87% at 1-year, respectively. One-year overall survival rate was excellent with 90%. Benchmark cutoffs included Comprehensive Complication Index CCI ® at 1-year of ≤72, and in-hospital and 1-year mortality rates of ≤13% and ≤15%, respectively. In contrast, patients who received a redo-LT for PNF showed worse outcomes with some values dramatically outside the redo-LT benchmarks.
CONCLUSION
This study shows that redo-LT achieves good outcome when looking at benchmark scenarios. However, this figure changes in high-risk redo-LT, as for example in PNF. This analysis objectifies for the first-time results and efforts for redo-LT and can serve as a basis for discussion about the use of scarce resources.

Identifiants

pubmed: 35894428
doi: 10.1097/SLA.0000000000005634
pii: 00000658-202211000-00017
pmc: PMC9983740
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

860-867

Informations de copyright

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest.

Références

Santopaolo F, Lenci I, Milana M, et al. Liver transplantation for hepatocellular carcinoma: where do we stand? World J Gastroenterol. 2019;25:2591–2602.
Ostojic A, Mrzljak A, Mikulic D. Liver transplantation for benign liver tumors. World J Hepatol. 2021;13:1098–1106.
Spolverato G, Bagante F, Tsilimigras DI, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors. Minerva Chir. 2019;74:399–406.
Merion RM, Goodrich NP, Feng S. How can we define expanded criteria for liver donors? J Hepatol. 2006;45:484–488.
Bodzin AS, Baker TB. Liver transplantation today: where we are now and where we are going. Liver Transpl. 2018;24:1470–1475.
Berumen J, Hemming A. Liver retransplantation: how much is too much? Clin Liver Dis. 2017;21:435–447.
Llado L, Lopez-Dominguez J, Ramos E, et al. Is liver retransplantation justified in the current era? Cir Esp (Engl Ed). 2021;99:339–345.
Muller X, Marcon F, Sapisochin G, et al. Defining benchmarks in liver transplantation: a multicenter outcome analysis determining best achievable results. Ann Surg. 2018;267:419–425.
Schlegel A, van Reeven M, Croome K, et al. A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation. J Hepatol. 2022;76:371–382.
Rossler F, Sapisochin G, Song G, et al. Defining benchmarks for major liver surgery: a multicenter analysis of 5202 living liver donors. Ann Surg. 2016;264:492–500.
Schmidt HM, Gisbertz SS, Moons J, et al. Defining benchmarks for transthoracic esophagectomy: a multicenter analysis of total minimally invasive esophagectomy in low risk patients. Ann Surg. 2017;266:814–821.
Sanchez-Velazquez P, Muller X, Malleo G, et al. Benchmarks in pancreatic surgery: a novel tool for unbiased outcome comparisons. Ann Surg. 2019;270:211–218.
Raptis DA, Linecker M, Kambakamba P, et al. Defining benchmark outcomes for ALPPS. Ann Surg. 2019;270:835–841.
Raptis DA, Sanchez-Velazquez P, Machairas N, et al. Defining benchmark outcomes for pancreatoduodenectomy with portomesenteric venous resection. Ann Surg. 2020;272:731–737.
Gero D, Raptis DA, Vleeschouwers W, et al. Defining global benchmarks in bariatric surgery: a retrospective multicenter analysis of minimally invasive Roux-en-Y gastric bypass and sleeve gastrectomy. Ann Surg. 2019;270:859–867.
Gero D, Vannijvel M, Okkema S, et al. Defining global benchmarks in elective secondary bariatric surgery comprising conversional, revisional, and reversal procedures. Ann Surg. 2021;274:821–828.
Mueller M, Breuer E, Mizuno T, et al. Perihilar cholangiocarcinoma—novel benchmark values for surgical and oncological outcomes from 24 expert centers. Ann Surg. 2021;274:780–788.
Gero D, Muller X, Staiger RD, et al. How to establish benchmarks for surgical outcomes? A checklist based on an international expert Delphi consensus. Ann Surg. 2022;275:115–120.
Croome KP, Lee DD, Perry DK, et al. Comparison of longterm outcomes and quality of life in recipients of donation after cardiac death liver grafts with a propensity-matched cohort. Liver Transpl. 2017;23:342–351.
Dubbeld J, Hoekstra H, Farid W, et al. Similar liver transplantation survival with selected cardiac death donors and brain death donors. Br J Surg. 2010;97:744–753.
Goldberg DS, Karp SJ, McCauley ME, et al. Interpreting outcomes in DCDD liver transplantation: first report of the multicenter IDOL consortium. Transplantation. 2017;101:1067–1073.
Laing RW, Scalera I, Isaac J, et al. Liver transplantation using grafts from donors after circulatory death: a propensity score-matched study from a single center. Am J Transplant. 2016;16:1795–1804.
Dutkowski P, Oberkofler CE, Slankamenac K, et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg. 2011;254:745–753; discussion 753.
Ghabril M, Agarwal S, Lacerda M, et al. Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation: analysis of risk factors and outcomes for portal vein thrombosis in waitlisted patients. Transplantation. 2016;100:126–133.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213.
Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–196.
Slankamenac K, Graf R, Barkun J, et al. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013;258:1–7.
Team RC. A Language And Environment For Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.
Staiger RD, Schwandt H, Puhan MA, et al. Improving surgical outcomes through benchmarking. Br J Surg. 2019;106:59–64.
Terho P, Sallinen V, Leppaniemi A, et al. Does the surgeon’s caseload affect the outcome in laparoscopic cholecystectomy for acute cholecystitis? Surg Laparosc Endosc Percutan Tech. 2020;30:522–528.

Auteurs

Fariba Abbassi (F)

Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.

Daniel Gero (D)

Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.

Xavier Muller (X)

Department of General, Abdominal and Transplant Surgery, Croix-Rousse Hospital, Lyon, France.

Alba Bueno (A)

Institute of Liver Studies, Kings' College Hospital, London, UK.

Wojciech Figiel (W)

Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Fabien Robin (F)

Department of HPB Surgery and Transplantation, University Hospital Rennes, Rennes, France.

Sophie Laroche (S)

Department of Surgery and Transplantation, the Hepatobiliary Center at Paul Brousse Hospital, Villejuif, France.

Benjamin Picard (B)

Department of Anesthesiology, Critical Care and Perioperative Medicine, DMU PARABOL, APHP.Nord, Hôpital Beaujon, Clichy, France.

Sadhana Shankar (S)

Department of Abdominal Transplant and Hepatobiliary Surgery, The Leeds Teaching Hospital trust, Leeds, UK.

Tommy Ivanics (T)

Multi-Organ Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.
Department of Surgery, Henry Ford Hospital, Detroit, MI.
Department of Surgical Sciences, Akademiska Sjukhuset, Uppsala University, Uppsala, Sweden.

Marjolein van Reeven (M)

Department of Surgery, Division of HPB & Transplant Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Otto B van Leeuwen (OB)

Division of HPB Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

Hillary J Braun (HJ)

Division of Transplant Surgery, University of California, San Francisco, CA.

Diethard Monbaliu (D)

Department of Abdominal Transplant Surgery and Transplant Coordination. University Hospitals Leuven, Leuven, Belgium.

Antoine Breton (A)

Department of General, Abdominal and Transplant Surgery, Croix-Rousse Hospital, Lyon, France.

Neeta Vachharajani (N)

Division of Abdominal Transplantation, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO.

Eliano Bonaccorsi Riani (E)

Department of Abdominal and Transplant Surgery, University Hospital St. Luc, Brussels, Belgium.

Greg Nowak (G)

Department of Transplantation Surgery, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Robert R McMillan (RR)

Houston Methodist Hospital, Weill Cornell Medical Center, Houston, TX.

Samir Abu-Gazala (S)

Department of Surgery, Penn Transplant Institute, Hospital of the University of Pennsylvania, Philadelphia, PA.

Amit Nair (A)

Division of Transplantation and Hepatobiliary Surgery, University of Rochester, Rochester, MN.

Rocio Bruballa (R)

HPB and Liver Transplant Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Flavio Paterno (F)

Division of Liver Transplant, Rutgers New Jersey Medical School University Hospital, Newark, NJ.

Deborah Weppler Sears (D)

Department of Abdominal and Transplant Surgery, Cleveland Clinic Florida, Weston, FL.

Antonio D Pinna (AD)

Department of Abdominal and Transplant Surgery, Cleveland Clinic Florida, Weston, FL.

James V Guarrera (JV)

Division of Liver Transplant, Rutgers New Jersey Medical School University Hospital, Newark, NJ.

Eduardo de Santibañes (E)

HPB and Liver Transplant Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Martin de Santibañes (M)

HPB and Liver Transplant Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Roberto Hernandez-Alejandro (R)

Division of Transplantation and Hepatobiliary Surgery, University of Rochester, Rochester, MN.

Kim Olthoff (K)

Department of Surgery, Penn Transplant Institute, Hospital of the University of Pennsylvania, Philadelphia, PA.

R Mark Ghobrial (RM)

Houston Methodist Hospital, Weill Cornell Medical Center, Houston, TX.

Bo-Göran Ericzon (BG)

Department of Transplantation Surgery, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Olga Ciccarelli (O)

Department of Abdominal and Transplant Surgery, University Hospital St. Luc, Brussels, Belgium.

William C Chapman (WC)

Division of Abdominal Transplantation, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO.

Jean-Yves Mabrut (JY)

Department of General, Abdominal and Transplant Surgery, Croix-Rousse Hospital, Lyon, France.

Jacques Pirenne (J)

Department of Abdominal Transplant Surgery and Transplant Coordination. University Hospitals Leuven, Leuven, Belgium.

Beat Müllhaupt (B)

Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.

Nancy L Ascher (NL)

Division of Transplant Surgery, University of California, San Francisco, CA.

Robert J Porte (RJ)

Division of HPB Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

Vincent E de Meijer (VE)

Division of HPB Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.

Wojciech G Polak (WG)

Department of Surgery, Division of HPB & Transplant Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Gonzalo Sapisochin (G)

Multi-Organ Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.

Magdy Attia (M)

Department of Abdominal Transplant and Hepatobiliary Surgery, The Leeds Teaching Hospital trust, Leeds, UK.

Olivier Soubrane (O)

Department of HPB surgery and liver transplantation, DMU DIGEST, APHP.Nord, Hôpital Beaujon, Clichy, France.

Emmanuel Weiss (E)

Department of Anesthesiology, Critical Care and Perioperative Medicine, DMU PARABOL, APHP.Nord, Hôpital Beaujon, Clichy, France.

René A Adam (RA)

Department of Surgery and Transplantation, the Hepatobiliary Center at Paul Brousse Hospital, Villejuif, France.

Daniel Cherqui (D)

Department of Surgery and Transplantation, the Hepatobiliary Center at Paul Brousse Hospital, Villejuif, France.

Karim Boudjema (K)

Department of HPB Surgery and Transplantation, University Hospital Rennes, Rennes, France.

Krzysztof Zieniewicz (K)

Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Wayel Jassem (W)

Institute of Liver Studies, Kings' College Hospital, London, UK.

Philipp Dutkowski (P)

Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.

Pierre-Alain Clavien (PA)

Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH